Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 4OTHER_GOV 2NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 267Triple Negative Breast Neoplasms 18Neoplasms 9Lymphedema 9Motor Activity 8Breast Cancer Lymphedema 8Breast Cancer Female 8Pathologic Complete Response 6Neoplasm Metastasis 6Colorectal Neoplasms 6Colonic Neoplasms 6Pain 5Fatigue 5Stomach Neoplasms 4Pain, Postoperative 4Recurrence 3Radiodermatitis 3Hereditary Breast and Ovarian Cancer Syndrome 3Endometrial Neoplasms 3Drug-Related Side Effects and Adverse Reactions 3Breast Diseases 3Advanced Breast Cancer 3Treatment Adherence and Compliance 2Thyroid Neoplasms 2Seroma 2Radiation Injuries 2Ovarian Neoplasms 2Melanoma 2Lymphoma 2Lung Neoplasms 2

Interventions

pyrotinib 2Trastuzumab 2Vinorelbine 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × HER2 Positive Breast Cancer × Breast × Clear all
NCT03735966 2022-12-01

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.

Henan Cancer Hospital

Phase 2 Completed
75 enrolled
Breast

HER2 Positive Breast Cancer

NCT03947242 2019-05-15

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.

Henan Cancer Hospital

Phase NA Unknown
48 enrolled
Breast

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡